Abstract
Inhibitors of mammalian target of rapamycin function to downregulate cell growth and proliferation and have off‐label use in pediatrics for vascular malformations. Hypertriglyceridemia is a known side effect of mammalian target of rapamycin (mTOR) inhibitors. Further studies to better understand the incidence and treatment of hypertriglyceridemia in infants and neonates are warranted.